Audrey Hollingsworth
About Audrey Hollingsworth
Audrey Hollingsworth is a Senior Associate Scientist at Asher Biotherapeutics, with a background in biological sciences and extensive research experience in nanoparticle evaluation and immunotherapy. She has previously held positions at GenEdit and the Children's Hospital Oakland Research Institute, contributing to significant studies in cancer therapy and gene delivery.
Current Role at Asher Biotherapeutics
Audrey Hollingsworth serves as a Senior Associate Scientist at Asher Biotherapeutics, a position she has held since 2022. In this role, she focuses on advancing biotherapeutic solutions, contributing her expertise in biological sciences to the organization's research initiatives. Her work involves significant contributions to the development and evaluation of innovative therapies.
Previous Experience at GenEdit
Prior to her current role, Hollingsworth worked at GenEdit from 2020 to 2022. She held two positions during her tenure: Senior Research Associate and Associate Scientist. Her work at GenEdit involved research and development in gene editing technologies, contributing to advancements in the field while based in South San Francisco, California.
Research Background at Children's Hospital Oakland Research Institute
Before joining GenEdit, Hollingsworth was employed as a Staff Research Associate at the Children's Hospital Oakland Research Institute from 2018 to 2020. In this capacity, she engaged in various research projects, enhancing her skills in scientific inquiry and laboratory techniques.
Educational Qualifications
Hollingsworth earned her Bachelor of Science (BS) degree in Biology/Biological Sciences from California State University, Chico, where she studied from 2012 to 2015. Her academic background provided a strong foundation in biological sciences, which she has applied throughout her professional career.
Research Contributions and Presentations
Hollingsworth has made significant contributions to various research projects, including studies on mRNA, siRNA, DNA, and CRISPR-Cas9 cargo delivery in vivo. She has participated in research presented at notable conferences such as the American Society of Hematology (ASH) in December 2022 and the American Association of Cancer Research (AACR) in April 2023. Additionally, she is involved in upcoming presentations at the Society for Immunotherapy of Cancer (SITC) in November 2023.